SecBot SecBot

ATHE

ALTERITY THERAPEUTICS LTD
Nasdaq· Pharmaceutical Preparations· Inc. C3· CIK 0001131343 Biotech & Drug Discovery
$2.08 −0.01 (−0.48%)
Oct 26 4:00 PM ET · prev $2.09
Market cap
$39.1M
Nano cap
Consensus
Buy
80% Buy or better · 5 analysts
Median target
$13.50
+549% · range $10.00–16.00
1 year
−53.9%
from $4.51 · Oct 27
30 days
−40.6%
from $3.50
52-week range
$2.08–5.89
at the low
Avg volume 20D
32.8K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$71.4K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
36
analyzed by SecBot
SecBot read MIXED 25 reports · 90 days
Balance 1 bearish · 3 bullish · 21 neutral oldest → newest, height = score
Avg score ·High conf. 22/25
Strongest BULLISH Alterity Therapeutics announced that its Phase 2 trial of ATH434 50 mg in Multiple System Atrophy (MSA) met…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $71.4K. No open-market sales.

  • InstitutionsBULLISH

    Q2 2026: 4 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    4 of 5 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $2.08 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GREENLEAF TRUSTADD62,000$332.9K
CITADEL ADVISORS LLCADD37,597$201.9K
BNP PARIBAS FINANCIAL MARKETSADD10,239$55.0K
Farther Finance Advisors, LLCADD39$205.00
RHUMBLINE ADVISERSDOUBLED2,127$6.5K
OSAIC HOLDINGS, INC.TRIM81$247.00
CITIGROUP INCNEAR_EXIT1$3.00
GREENLEAF TRUSTADD32,000$120.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

5 analysts
Buy 80% rate it Buy or better
Strong Buy1Buy3Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +549%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 15, 2026Lake Street
INITIATE
INITIATEBuy
Aug 11, 2026Craig-Hallum
INITIATE
INITIATEBuy
Jun 30, 2026Jones Trading
INITIATE
INITIATEBuy

Insider ledger

Form 4
$71.4K
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Aug 31, 2026
Marks Peter Ashley
Director
BUY$23.8K
Aug 31, 2026
Marks Peter Ashley
Director
BUY$23.8K
Aug 31, 2026
Stamler David Allen
Chief Executive Officer
BUY$23.8K
Jun 15, 2026
Gozlan Lawrence Bernard
Director
AWARD1,000,000 sh
Jun 15, 2026
Babarczy Julian Michael
Director
AWARD2,000,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.77-$1.18–-$0.21+37.0%$1.1M
Next FY-$0.96-$1.26–-$0.41+24.2%$2.0M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Alterity Therapeutics filed a 6-K with an Exhibit 99.1 titled 'Proposed issue of securities - ATH', indicating a…
6-K — Impact 6/10
Oct 23, 2026 SEC
Alterity Therapeutics filed a Form 6-K with an exhibit (Exhibit 99.1) titled 'Notification regarding unquoted…
6-K — Impact 2/10
Oct 23, 2026 SEC
Alterity Therapeutics filed a Form 6-K on October 23, 2026, solely to submit an Exhibit 99.1 notification regarding…
6-K — Impact 2/10
Oct 5, 2026 Press
Alterity Therapeutics announced that its Phase 2 trial of ATH434 50 mg in Multiple System Atrophy (MSA) met its…
Impact 8/10
Oct 5, 2026 FDA
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on t
Aug 31, 2026 Insider
Marks Peter Ashley bought 47,620 shares
Director @ $0.5000 ($23.8K)
Aug 31, 2026 Insider
Marks Peter Ashley bought 47,620 shares
Director @ $0.5000 ($23.8K)
Aug 31, 2026 Insider
Stamler David Allen bought 47,620 shares
Chief Executive Officer @ $0.5000 ($23.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 5, 2026
FDA
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a…
Sep 3, 2026
Press release
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…
Aug 12, 2026
Press release
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial…
Aug 6, 2026
Press release
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…
Jul 30, 2026
Earnings
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Highlights

SecBot reports

36 filings · 6 press releases · 3 bullish · 1 bearish · 32 neutral
All ATHE filing & press-release reports (42)